Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB04 versus EU- and US-sourced Enbrel pharmacokinetic crossover study in healthy male volunteers
NL-OMON60489Phase 1Completed
- Sponsor
- mAbxience
- Start
- Feb 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of etanercept (2 arms), sponsored by mAbxience. Primary endpoint: Primary endpoint(s). Started Feb 2024; status: completed.
02
Drugs
etanercept
Beyond the preview
Go deeper on NL-OMON60489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60489.